One thing federal regulators decided to start counting, and one thing they decided to stop counting, arrived in the same Medicare Advantage rule. Depression screening becomes a scored quality measure with data collection starting in the 2027 measurement year and a score first appearing in 2029 Star Ratings; a separate requirement that plan quality-improvement programs address health disparities is eliminated outright, a pairing CMS frames as regulatory streamlining rather than a retreat from equity work. Star Ratings decide which plans qualify for quality bonus payments that fund richer benefits, so what CMS measures, or stops measuring, shapes what a beneficiary’s plan can offer.
A New Part C Measure Targets Depression Screening and Follow-Up
Medicare Advantage plans are rated every year on a defined set of clinical, service and member-experience measures that CMS calls Part C and Part D measures, and the agency periodically adds or drops measures as it identifies gaps in what the existing set captures. The addition finalized in the contract-year 2027 Medicare Advantage and Part D rule targets behavioral health specifically: a measure asking whether a plan screened a member for depression and, separately, whether a positive screening result led to documented follow-up care rather than stopping at the screening step.
CMS’s own fact sheet describes the change directly: the agency is adding a new Part C Depression Screening and Follow-Up measure to address behavioral health gaps starting with the 2027 measurement year and 2029 Star Ratings. That two-year gap is not a delay CMS built in for this measure alone; Star Ratings released in a given year are always built from data collected roughly two years earlier, which is why 2027 performance surfaces in the 2029 ratings rather than sooner. The Federal Register text of the same rule lists the change under its own heading, confirming it as a standalone addition rather than a revision of an existing screening item.
Free retirement updates: Plain-English updates on the changes, deadlines, and costly mistakes retirees miss, from the free Retirement Shield newsletter. Subscribe free.
How a Star Rating Becomes a Plan’s Bonus Payment
Star Ratings exist for more than consumer comparison shopping. A plan’s overall rating determines whether it qualifies for a quality bonus payment, and CMS scores Medicare Advantage Prescription Drug contracts, plans that bundle Medicare Advantage with drug coverage, on up to 43 separate measures, Medicare Advantage-only contracts on up to 33, and standalone Part D drug plans on up to 12, grouped into five categories: outcomes, intermediate outcomes, process, patient experience, and access. The new depression-screening measure adds one more line to that MA-PD count once it takes effect.
CMS’s most recent published Star Ratings fact sheet spells out the payment link for the current cycle: the 2026 Star Ratings, now posted on Medicare Plan Finder for open enrollment, will impact 2027 Medicare Advantage quality bonus payments. The same fact sheet reports that about 40% of MA-PD contracts earned four stars or higher for 2026, covering roughly 64% of MA-PD enrollees by weighted enrollment, meaning most Medicare Advantage members are currently in plans whose bonus-eligible status depends on a Star Rating built from measures the depression-screening addition is about to join.
That enrollment concentration is why a single added measure carries real financial weight. Quality bonus payments do not go to every plan; the fact sheet’s own data show ratings compress heavily around the middle, with roughly a third of MA-PD contracts sitting at 3.5 stars in 2026, just below the four-star bonus threshold most plans compete to clear. A contract’s performance on the new depression-screening measure, once it is folded into that scoring in 2029, could be the difference for plans already sitting near that line.
CMS does not publish, in the fact sheet describing the new measure, what weight the depression-screening item will carry relative to the 42 or more measures already in the MA-PD scoring set, or how it will be blended into the five weighted categories the agency already uses. Plans will not know the measure’s practical effect on their bonus eligibility until CMS finalizes technical notes closer to the 2029 ratings cycle, leaving a real gap between the policy taking effect now and its financial consequences becoming visible.
The Health-Equity Requirement CMS Is Retiring in the Same Rule
The same CY2027 rule that adds the depression-screening measure removes a requirement running in the opposite direction. CMS’s fact sheet lists eliminating the requirement for MA quality-improvement programs to include activities that reduce health disparities among the provisions finalized to cut regulatory burden, filing the change under a section tied to Executive Order 14192 rather than presenting it as a judgment on the value of that work.
A related provision in the same section drops the health-equity requirements attached specifically to MA Utilization Management Committees, including the mandate that each committee include a health-equity expert member, conduct annual health-equity analyses, and publicly post those analyses. Both eliminations apply starting the same contract year as the new depression-screening measure, so plans lose a structural equity-review obligation in the identical rule that adds a single clinical measure aimed at one behavioral-health gap.
CMS’s fact sheet does not address whether the narrower depression-screening measure is meant to substitute for the broader disparity-reduction work it is eliminating; the two provisions sit in separate sections of the same document with no cross-reference between them. What plans will be required to measure going forward is narrower than what was required before: screen for depression and document follow-up, without the annual health-equity analysis or committee-level review that used to accompany it.
That leaves an open question the rule itself does not resolve: whether one specific behavioral-health measure, added to a scoring system already carrying up to 43 items, can meaningfully substitute for the broader disparity-reduction infrastructure CMS is dismantling in the same document. The 2029 Star Ratings will be the first place the answer becomes visible, showing not just whether Medicare Advantage plans screened members for depression and followed up, but whether removing the equity-reporting requirement changed which members got screened at all, a comparison CMS’s current fact sheet gives no way to make.
This article was produced with AI assistance and reviewed by The Money Overview editorial team.
More Financial Reading
